The role of PI3K inhibitors in the treatment of malignant lymphomas
- 2 November 2020
- journal article
- other
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 62 (3) , 517-527
Abstract
Deregulated phosphatidylinositide 3-kinase (PI3K) signaling plays a crucial role in the biology of different lymphoma entities leading to the proliferation and survival of the malignant cells. Due to novel treatment options and modern supportive care, the outcome of patients with lymphomas has significantly improved in the past years. However, patients with relapsed or refractory disease still have a limited prognosis. PI3K inhibitors represent a modern and effective therapeutic option for patients with different types of lymphoma. However, the efficacy of PI3K inhibitors varies among lymphoma entities. Additionally, severe toxicity including infectious and autoimmune complications leading to therapy-related deaths has been observed. Next-generation PI3K inhibitors show promising efficacy and manageable toxicity profiles. Future research might identify effective combinatorial therapy approaches for PI3K inhibitors to further improve response rates. This review discusses the most recent developments in the field of PI3K inhibition in different subtypes of lymphoma.Keywords
This publication has 96 references indexed in Scilit:
- Functional Characterization of an Isoform-Selective Inhibitor of PI3K-p110β as a Potential Anticancer AgentCancer Discovery, 2012
- Effect of PI3K- and mTOR-specific inhibitors on spontaneous B-cell follicular lymphomas in PTEN/LKB1-deficient miceBritish Journal of Cancer, 2011
- A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphomaLeukemia, 2010
- Chronic active B-cell-receptor signalling in diffuse large B-cell lymphomaNature, 2010
- Essential roles of PI(3)K–p110β in cell growth, metabolism and tumorigenesisNature, 2008
- AKT/PKB Signaling: Navigating DownstreamCell, 2007
- Only Akt1 Is Required for Proliferation, while Akt2 Promotes Cell Cycle Exit through p21 BindingMolecular and Cellular Biology, 2006
- The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolismNature Reviews Genetics, 2006
- Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesisNature Reviews Cancer, 2006
- Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitiveNature Cell Biology, 2004